GlobalData Plc

Sales for chronic kidney disease (CKD)-induced hyperparathyroidism (HPT), hyperphosphatemia (HP), and hyperkalemia (HK) therapeutics were estimated to be $4.2bn across the seven major markets (7MM*) in 2016. This is expected to grow to $10.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 9.5%, according to GlobalData, a leading data and analytics company.

The company’s report: ‘OpportunityAnalyzer: Late – Stage Chronic Kidney Disease’ states that over the forecast period, the most prominent wave of sales increases will come from the launch of new HK agents and the calcimimetic, Parsabiv, which will counteract the loss of market exclusivity of its in-house predecessor, Sensipar (cinacalcet).

One of the most prominent clinical issues surrounding the HPT, HP, and HK space is patient compliance with current therapy options. This is observed across the board for all available therapeutic classes, whether in the form of the pill burden of the phosphate and potassium binders, gastrointestinal (GI) toxicity in the calcimimetics, or the life-long administration of vitamin D sterols.

Jesus Cuaron, PhD, Healthcare Analyst at GlobalData, comments: “Although patient compliance is an area with the highest unmet needs, the present trend in corporate strategy highlights the fact that recent advancements have been suboptimal, as they involve non-novel approaches to improve current treatment options by developing ‘me-too’ drugs instead of transformative therapies.”

Resins have been considered the standard of care for treating non-emergency acute and chronic CKD-induced HK patients following diet and lifestyle modifications and/or lowering potassium intake. However, resins have an unpredictable onset of action, adverse GI effects, bad taste, and a sodium or calcium presence, which have made nephrologists uneasy when prescribing these treatments in heart failure and CKD patients. As such, the arrival of new HK agents with preferable clinical profiles has been long awaited.

Cuaron continues: “Currently, there is only one novel HK agent on the market, Vifor’s Veltassa, which launched in the US in 2016. Key opinion leaders agree that Veltassa has more robust positive clinical data and preferable patient compliance for patients suffering CKD-induced HK compared to outcomes seen with resin treatment.”

Amgen’s Parsabiv is a second-generation IV calcimimetic for the treatment of dialysis-dependent HPT patients. Parsabiv is vying for a robust launch into the HPT market. Parsabiv has been evaluated in several Phase III studies, and has shown superior results in a head-to-head study against the first-in-class calcimimetic, cinacalcet, as well as encouraging results from placebo-controlled studies, all of which instil physician confidence in Parsabiv’s capability to treat HPT dialysis patients.

Cuaron adds: “Parsabiv is the first IV calcimimetic in the HPT arena and will thus avoid the associated compliance issues observed with oral cinacalcet. We believe that it will acquire a critical market position, revolutionizing the treatment of secondary HPT.”

Information based on GlobalData’s report: OpportunityAnalyzer: Late – Stage Chronic Kidney Disease – Opportunity Analysis and Forecasts to 2026

* 7MM: US, France, Germany, Italy, Spain, UK and Japan.

Related Intelligence

Want more Insight like this?

Our interactive subscription platform has the most comprehensive data and analysis in your industry.

Request a Demo

Related Consulting

How can we help your business?

Our consultants are skilled in every specialist market niche to deliver solutions specifically designed for your individual requirements.

Request a Callback

    Press Release Healthcare

    Therapeutic application of mAbs will increase in near future, says GlobalData

    Ever since the first commercial monoclonal antibodies (mAbs) was approved in 1986 for human therapeutic purposes, mAbs have been increasingly used in several areas of healthcare. According to GlobalData, a leading data and analytics company, the total number of clinical trials involving mAbs witnessed a robust 115% growth between 2007 and 2016. The company’s Clinical...

    Press Release Healthcare

    General surgery market is set to reach $21.6bn by 2024

    The general surgery market is forecast to grow steadily moving into the next decade. The market was valued at $14.6 bn in 2017 and is expected to reach a value of $21.6 bn in 2024, increasing at a Compound Annual Growth Rate (CAGR) of 5.7%, according to according to GlobalData, a leading data and analytics company.

    Press Release Healthcare

    Majority of oncology clinical trials in China failed to meet enrolment targets

    The majority of oncology clinical trials in China that had a start date between 1 January 2012 and 31 December 2017 failed to meet the planned enrolment targets, according to GlobalData, a leading data and analytics company. The company identified and analyzed enrollment efficiencies of 324 clinical trials during the period and found that on...

    Press Release Healthcare

    Need for supportive care in oncology will increase during the next decade

    The need for effective supportive care in oncology will increase in the next decade as patients continue to live longer and cancer progresses to become more like a chronic disease. This includes the need for chemotherapy-related conditions, as chemotherapy will remain the backbone of cancer therapy for the foreseeable future, observes GlobalData, a leading data and analytics company.

    Press Release Healthcare

    World Cancer Day: What will 2018 mean for cancer research and treatment?

    The theme of this year’s World Cancer Day held on 4th February of “We can. I can.” aimed to reinforce the public message that all individuals and groups can play their part in reducing the global burden of cancer. Indeed in recent years many events have involved collaborations between traditional drug developers, cancer treatment professionals and those of varying disciplines. Examples include the IBM Watson supercomputer which is helping physicians make treatment decisions and the development of other databases such as ASCO’s CancerLinQ which assists oncologists in monitoring and analyzing patient data.

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we’re very happy to help.
PhoneEMEA: +44 207 832 4399
PhoneAPAC: +91 40 6616 6809
Onlinecontact online

56% of #consumers are concerned about the impact of diet. Join us for more insight @incosmetics #cosmetics #trends…